Supplementary Figures 1-7 from Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound d-1-Methyl-Tryptophan
Open Access
- 30 March 2023
- other
- Published by American Association for Cancer Research (AACR)
Abstract
Supplementary Figures 1-7 from Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound d-1-Methyl-TryptophanKeywords
This publication has 0 references indexed in Scilit: